Navigation Links
Delcath Systems Reports Substantial Progress
Date:11/19/2009

ery well positioned to execute on our strategies, expand the potential benefits of the PHP System to patients globally and build increasing returns to our shareholders."

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical device company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake n
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems, Inc. Prices $30.6 Million Stock Offering
11. Delcath Systems Announces Completion of Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Instrumentation Laboratory (IL) today announced the launch of its ... is part of a comprehensive rebranding effort by Werfen, the ... Boston, MA , in 1959, IL has been part ... companies in the group include Inova Diagnostics ( San ... Spain ).  Like IL, these three companies are focused ...
(Date:7/29/2014)... Research and Markets has announced the addition ... report to their offering. ... medical device used to provide medication or assist a ... achieve adequate oxygen levels to maintain life. Patients with ... ARDS require the need of respiratory devices. The medication ...
(Date:7/29/2014)... , July 29, 2014  Based on its ... (PERS) market, Frost & Sullivan recognizes MobileHelp with ... for Price Performance Value Leadership. MobileHelp,s leadership in ... expectations for tech progression in personal emergency response, ... these solutions. MobileHelp is at the ...
Breaking Medicine Technology:Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Global Respiratory Devices Market 2014-2018 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3
... Horizon Pharma, Inc. announced today that it has filed a registration statement ... a proposed initial public offering of shares of its common stock.  All shares ... by the Company. , , , ... & Company, Inc. and Piper Jaffray & Co. are acting as ...
... Pharmaceuticals (NYSE: WPI ) today announced that ... as Senior Vice President, Global Operations, has been promoted to Executive Vice ... Bisaro , President and Chief Executive Officer of Watson. , ... Mr. Stewart will assume responsibility ...
Cached Medicine Technology:Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering 2Watson Promotes Robert Stewart to Executive Vice President, Global Operations 2Watson Promotes Robert Stewart to Executive Vice President, Global Operations 3
(Date:7/29/2014)... 2014 DailyGossip.org reveals in its latest review ... who can perfectly understand patients and what they have to ... Gadsby is the author of the new program. Ellie claims ... of suffering, Ellie started her very own research. Four years ... The author of the Get Rid of Cold Sores program ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural ... created by a popular nutritionist and health specialist. Michael ... for this disorder, but none of them worked. , ... of having to look for an alternative vitiligo treatment, ... this method, too, to become vitiligo free. , ...
(Date:7/29/2014)... 2014 For survivors of severe combat injuries threatening ... flaps have a good record of safety and effectiveness ... issue of Plastic and Reconstructive Surgery ... Society of Plastic Surgeons (ASPS). , Experience with ... and Afghanistan shows good success rates, with no increase ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
(Date:7/29/2014)... NH (July 29, 2014) Using quality improvement measures ... New England Cardiovascular Disease Study Group, researchers have found ... a procedure with contrast dye. , Currently, 7-15 percent ... with contrast-dye end up with kidney injury, which can ... leading to temporary or permanent dialysis, says a study ...
Breaking Medicine News(10 mins):Health News:Get Rid of Cold Sores Fast Review Exposes the Way to Stop Outbreaks 2Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Reducing kidney injury using a quality improvement method 2
... Doctor, Health officials of the NHS Grampian said that people ... // The NHS health board said so defending their decision ... wards. ,A spokeswoman for NHS Grampian said a ... be suitable for a patient to stay outwith the city's ...
... is a fungal infection affecting mostly children in North America. ... affected by ringworm infections. //It is a highly contagious skin ... symptoms such as scaly scalp and hair loss which can ... household pets but in rare occasions it is passed easily ...
... The authorities in Delhi have blamed the poor quality of ... the last four months. So far 222 cases have been ... against 92 in the corresponding period last year. But we ... well under control," said N.K. Yadav, deputy municipal health officer ...
... Zealand have warned against using traditional Indian medicines after ... reported Friday.// ,"We wish to alert the medical ... a particular form of herbal remedy, namely, Ayurvedic medicine," ... Zealand Medical Journal. ,The eight patients suffered ...
... Delhi High Court has demanded an explanation from the medical ... boy suffering from cancer got inflicted with AIDS after undergoing ... an explanation on why the relevant documents were not being ... Sen ruled that the blood transfusion was the business of ...
... In the event of an influenza pandemic set into action by ... are we to handle// a mega crisis, and what plan of ... the responses to an epidemic, eight Asia Pacific countries are teaming ... gauge the effectiveness of a global response to a pandemic. ...
Cached Medicine News:
ELISA for detection of Anti-Gliadin IgA....
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Enzyme immunoassay for the quantitative determination of Gliadin-IgA antibodies in serum and plasma. This kit provides specific determination of gliadin antibodies by using highly purified gliadin....
... immunosorbent assay method for the semi-quantitative determination ... human serum. The results of the anti-Gliadin ... aid in the diagnosis of diseases associated ... Coeliac Disease. Levels of these autoantibodies are ...
Medicine Products: